CAS 26159-34-2 Naproxen Sodium (HCID 23681059)

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

CAS: 26159-34-2
Standard-SMILES: COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
InChIKey: CDBRNDSHEYLDJV-FVGYRXGTSA-M
Summenformel: C14H13NaO3
Durchschnittliche Molmasse: 252,24 g/mol
Monoisotopische Masse: 252,07623856

Überblick

Naproxen sodium is an organic sodium salt consisting of equimolar amounts of naproxen(1) anions and sodium anions. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, a cyclooxygenase 2 inhibitor and a cyclooxygenase 1 inhibitor. It contains a naproxen(1-).

Namen und Bezeichner

Bevorzugter Name: Naproxen Sodium
IUPAC: sodium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
Lokaler Name: Natrium-(-)-2-(6-methoxy-2-naphthyl)propionat
Englischer Name: Naproxen sodium
Summenformel: C14H13O3.Na
Molmasse: 253.25

Namen und Synonyme

naproxen sodium26159-34-2NaprelanNaproxen sodium saltMiranaxPrimeralNapriumNapruxDiocodalPrexanFlanaxANAPROX DS

Weitere Namen anzeigen

aleveAnax(S)-6-METHOXY-ALPHA-METHYL-2-NAPHTHALENEACETIC ACID SODIUM SALTAnaproxaproxen sodiumNAPROXENSODIUM,USPNaproxen Sodium (200 mg)Naproxen Sodium (1457403)

BAYH6689DTXSID7045576Naproxen sodium anhydrousTopcare all day pain reliefRS 3650RS-36509TN87S3A3CBAY117031

Datenbank-Bezeichner

CAS: 26159-34-2
PubChem CID: 23681059
DTXSID: DTXSID7045576
ChEMBL: CHEMBL1200806
ChEBI: CHEBI:7477
UNII: 9TN87S3A3C
EC Number: 247-486-2

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA): 49,4 Å²
H-Brücken-Donoren: 0
H-Brücken-Akzeptoren: 3
Frei drehbare Bindungen: 3
Schwere Atome: 18
Formalladung: 0
Komplexität: 282

Experimentelle und physikochemische Eigenschaften

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt: 250 · 250-251°C
Dichte: 1.2 g/cm³ · 1.2 g/cm³
storage temp.: Inert atmosphere,Room Temperature
Löslichkeit: Freely soluble in water, freely soluble or soluble in methanol, sparingly soluble in ethanol (96 per cent).
Aggregatzustand: Solid
Farbe: White to Off-White
Biologische Quelle: synthetic (organic)
Wasserlöslichkeit: 100 mg/mlSoluble · Soluble in water up to 100mg/mlSoluble in methanol and chloroform. Slightly soluble in ether. Insoluble in water.
Major Application: pharmaceutical (small molecule)
InChI: InChI=1/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/s3

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 0.7% (1 of 138) of reports.

Danger

H302 (60.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 138 reports by companies from 18 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationNaproxen sodium: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, sodium salt, (S)-: Environment tier I assessment

Hazard Classes and CategoriesAcute Tox. 4 (60.1%)

Sicherheitsdaten

wgk: 3
ridadr: 3249
hs_code: 2918992090
RTECS-Nr.: QJ1047000
risk_code: 22-61
hazard_code: Xn,T
safety_code: 53-45
hazard_class: 6.1(b)
packing_group: III
Speicherklasse: 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Chemie und Industrie

Pharmakologische Informationen

FDA Pharmacological Classification · 6 Einträge

NAPROXEN SODIUM

Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Anti-Inflammatory Agents, Non-Steroidal [CS]

NAPROXEN SODIUM 220 MG

Anti-Inflammatory Agents, Non-Steroidal [CS]; Nonsteroidal Anti-inflammatory Drug [EPC]; Cyclooxygenase Inhibitors [MoA]

NAPROXEN SODIUM 220MG

Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Anti-Inflammatory Agents, Non-Steroidal [CS]

MeSH Pharmacological Classification · 3 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Anwendungen · 1 Eintrag

VerwendenA cyclooxygenase inhibitorNaproxen sodium acts as a nonselective inhibitor of Cox-1 and Cox-2. It serves as an anti-inflammatory agent with analgesic and antipyretic properties. Further, it is used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea and acute gout.